Abstracts tagged "Clinical and tocilizumab"

Abstract Number: 2469 • 2014 ACR/ARHP Annual Meeting
The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks
Alan Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, S. C. Radominski⁶, Joan T. Merrill⁷, Jinglan Pei⁸, Lucy Rowell⁹, Clare Nasmyth-Miller⁹, Sunethra Wimalasundera⁹ and Janet E. Pope¹⁰, ¹Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ²Internal Medicine, Division of Rheumatology, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Genentech, South San Francisco, CA, ⁹Roche, Welwyn Garden City, United Kingdom, ¹⁰St Joseph Health Care, London, ON, Canada
Background/Purpose : The BREVACTA study assessed the efficacy and safety of subcutaneous tocilizumab (TCZ SC) in patients (pts) with RA who had an inadequate response…